Literature DB >> 17630864

Body mass indexes and lipid profiles in hospitalized children and adolescents exposed to atypical antipsychotics.

Nick C Patel1, Monica Hariparsad, Mary Matias-Akthar, Michael T Sorter, Drew H Barzman, John A Morrison, Kevin E Stanford, Stephen M Strakowski, Melissa P DelBello.   

Abstract

OBJECTIVE: The purpose of this study was to examine body mass indexes (BMI) and lipid profiles of children and adolescents hospitalized for a psychiatric illness and exposed to an atypical antipsychotic.
METHOD: Medical records of children and adolescents (ages of 5-18 years) with an inpatient psychiatric hospitalization between July 1, 2004, and June 30, 2005, were reviewed. Subjects were required to have been treated with at least one atypical antipsychotic during the month prior to admission. Height, weight, and fasting lipid values completed upon admission were collected. Prevalences of overweight (sex-specific BMI for age>or=the 95th percentile) and at risk for overweight (sex-specific BMI for age between the 85th and 94.9th percentiles) were determined and compared to estimates from the 2001-2002 National Health and Nutrition Examination Survey (NHANES) data. The prevalence of abnormal lipid profiles was also evaluated using widely accepted criteria specific for pediatric patients. Exploratory multiple linear regression models were fit to examine relationships of demographic and clinical variables with BMI z-scores and lipid profiles.
RESULTS: Of 95 inpatients (mean age 14 years, 43% female, and 60% white) evaluated, 16% (n=15) were at risk for overweight and 53% (n=50) were overweight. Fifty-one percent (n=48) and 48% (n=46) of the sample had elevated triglycerides (TG) levels and low high-density lipoprotein (HDL) levels, respectively.
CONCLUSION: The prevalence of overweight among hospitalized children and adolescents with exposure to atypical antipsychotics is triple that of national norms. Dyslipidemia was also common in this inpatient sample. Future studies should assess the development of overweight, the factors contributing to it, and related comorbidities in youths with mental illness.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17630864     DOI: 10.1089/cap.2006.0037

Source DB:  PubMed          Journal:  J Child Adolesc Psychopharmacol        ISSN: 1044-5463            Impact factor:   2.576


  16 in total

1.  First do no harm: promoting an evidence-based approach to atypical antipsychotic use in children and adolescents.

Authors:  Constadina Panagiotopoulos; Rebecca Ronsley; Dean Elbe; Jana Davidson; Derryck H Smith
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2010-05

2.  Multiple psychiatric diagnoses common in privately insured children on atypical antipsychotics.

Authors:  Donna R Halloran; Jason Swindle; Steve K Takemoto; Mark A Schnitzler
Journal:  Clin Pediatr (Phila)       Date:  2010-01-28       Impact factor: 1.168

3.  Medication use and spending trends among children with ADHD in Florida's Medicaid program, 1996-2005.

Authors:  Catherine A Fullerton; Arnold M Epstein; Richard G Frank; Sharon-Lise T Normand; Christina X Fu; Thomas G McGuire
Journal:  Psychiatr Serv       Date:  2012-02-01       Impact factor: 3.084

Review 4.  Pharmacotherapy of bipolar disorder in children and adolescents: recent progress.

Authors:  Jonathan C Pfeifer; Robert A Kowatch; Melissa P DelBello
Journal:  CNS Drugs       Date:  2010-07       Impact factor: 5.749

5.  Obesity identified by discharge ICD-9 codes underestimates the true prevalence of obesity in hospitalized children.

Authors:  Jessica G Woo; Meg H Zeller; Kimberly Wilson; Thomas Inge
Journal:  J Pediatr       Date:  2008-10-31       Impact factor: 4.406

Review 6.  Antipsychotic and psychostimulant drug combination therapy in attention deficit/hyperactivity and disruptive behavior disorders: a systematic review of efficacy and tolerability.

Authors:  David Linton; Alasdair M Barr; William G Honer; Ric M Procyshyn
Journal:  Curr Psychiatry Rep       Date:  2013-05       Impact factor: 5.285

7.  Antipsychotic polypharmacy in children and adolescents at discharge from psychiatric hospitalization.

Authors:  Shannon N Saldaña; Brooks R Keeshin; Anna M Wehry; Thomas J Blom; Michael T Sorter; Melissa P DelBello; Jeffrey R Strawn
Journal:  Pharmacotherapy       Date:  2014-07-03       Impact factor: 4.705

Review 8.  Prevalence and correlates of antipsychotic polypharmacy in children and adolescents receiving antipsychotic treatment.

Authors:  Nitin Toteja; Juan A Gallego; Ema Saito; Tobias Gerhard; Almut Winterstein; Mark Olfson; Christoph U Correll
Journal:  Int J Neuropsychopharmacol       Date:  2013-05-14       Impact factor: 5.176

Review 9.  Weight gain and increase of body mass index among children and adolescents treated with antipsychotics: a critical review.

Authors:  José María Martínez-Ortega; Silvia Funes-Godoy; Francisco Díaz-Atienza; Luis Gutiérrez-Rojas; Lucía Pérez-Costillas; Manuel Gurpegui
Journal:  Eur Child Adolesc Psychiatry       Date:  2013-03-17       Impact factor: 4.785

10.  Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents.

Authors:  Chadi A Calarge; Laura Acion; Samuel Kuperman; Michael Tansey; Janet A Schlechte
Journal:  J Child Adolesc Psychopharmacol       Date:  2009-04       Impact factor: 2.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.